Financial Assessment of the Global Pharmaceutical and Biotechnology Industry

Financial Management is the Key Strategy for Sustainability

Regular Price: USD 4,950

Special Price USD 4,208

15% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 4,208

PAY BY INVOICE

Be the first to review this product

This financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718 publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each industry are also highlighted.

Table of Contents

Financial Assessment of the Global Pharmaceutical and Biotechnology Industry, Assessment of Financial HealthAnalysis of Financial Ratios of Public Companies in the Global Pharmaceutical and Biotechnology IndustryFinancial Assessment of Participants of Pharmaceutical and Biotechnology Industry




Related Research

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.